SynBioBeta Speaker

Jean Hebert

ARPA-H

Program Manager

Dr. Jean Hebert joined ARPA-H in August 2024 from the Albert Einstein College of Medicine where he served as a professor of genetics and neuroscience. Hebert is the founder of BE Therapeutics, a company focused on reversing age-related damage to brain tissue. His laboratory research focused on cell-and tissue-based repair, plasticity, neurodegeneration, and cortical function. In addition to his academic publications, Hebert is also the author of Replacing Aging, a book on how regenerative medicine can address all forms of damage that accumulate in aging tissues.

Since childhood, Hebert has been interested in understanding how our bodies work and how to repair them. He has a doctorate in genetics from the University of California San Francisco and completed postdoctoral research at Stanford University studying the development of the neocortex.

SynBioBeta 2026 Tickets are Live

Confirmed Speakers

Sessions Featuring

Jean

This Year

Breakout Session

4:30 PM

-

5:15 PM

Human Health

Reconstructing the Body: Can Biological Replacement Reverse Aging?

Despite major advances in the biology of aging, there are still no interventions that clearly slow or reverse aging in humans. In contrast, modern medicine already depends on replacement to restore lost function, from artificial joints and cardiac devices to organ transplants and stem cell therapies. This session examines how a similar framework could be applied to aging: rather than repairing deteriorated cells and tissues, scientists and companies are exploring ways to replace them with newly generated, biologically young equivalents. The discussion will highlight emerging capabilities in engineered cell sources, scalable tissue fabrication, and programmable biology (instead of "integration") strategies that are redefining what can be rebuilt and replaced. New approaches are beginning to address long-standing challenges such as age-related signaling environments, vascularization, and even circuit compatibility in parts of the brain. Together, these advances point toward a future where rejuvenation is achieved through deliberate biological reconstruction. The session asks: How far can replacement take us, and could rebuilding youthful parts become a central path to extending healthy lifespan?

Purchase Pass

Breakout Session

4:30 PM

-

5:15 PM

Human Health

Reconstructing the Body: Can Biological Replacement Reverse Aging?

Despite major advances in the biology of aging, there are still no interventions that clearly slow or reverse aging in humans. In contrast, modern medicine already depends on replacement to restore lost function, from artificial joints and cardiac devices to organ transplants and stem cell therapies. This session examines how a similar framework could be applied to aging: rather than repairing deteriorated cells and tissues, scientists and companies are exploring ways to replace them with newly generated, biologically young equivalents. The discussion will highlight emerging capabilities in engineered cell sources, scalable tissue fabrication, and programmable biology (instead of "integration") strategies that are redefining what can be rebuilt and replaced. New approaches are beginning to address long-standing challenges such as age-related signaling environments, vascularization, and even circuit compatibility in parts of the brain. Together, these advances point toward a future where rejuvenation is achieved through deliberate biological reconstruction. The session asks: How far can replacement take us, and could rebuilding youthful parts become a central path to extending healthy lifespan?

Purchase Pass

TBD

Session lineup still growing

Purchase Pass

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Purchase Pass

Featuring

Speaker Coming Soon

Previous Speakers Include